Cargando…
The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies
INTRODUCTION: This study describes the results of the Belgian 'MabThera In Rheumatoid Arthritis (MIRA)' registry: effectiveness, safety and evaluation of the current retreatment practice on the background of the Belgian reimbursement criteria for rituximab. METHODS: All Belgian rheumatolog...
Autores principales: | Vander Cruyssen, Bert, Durez, Patrick, Westhovens, Rene, Kaiser, Marie-Joelle, Hoffman, Ilse, De Keyser, Filip |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990996/ https://www.ncbi.nlm.nih.gov/pubmed/20831776 http://dx.doi.org/10.1186/ar3129 |
Ejemplares similares
-
Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
por: Shpilberg, O, et al.
Publicado: (2013) -
Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®
por: Xu, Yanpeng, et al.
Publicado: (2019) -
Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma
por: Viswabandya, Auro, et al.
Publicado: (2019) -
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity
por: Vander Cruyssen, Bert, et al.
Publicado: (2010) -
A Double-Blind, Randomized Comparison Study between Zytux™ vs MabThera® in Treatment of CLL with FCR Regimen: Non-Inferiority Clinical Trial
por: Toogeh, Gholamreza, et al.
Publicado: (2018)